The MAPK cascade plays a crucial role in tumor cell proliferation and survival. Accumulating evidence suggests that mutations in the BRAF oncogene are not only associated with poor prognosis but also linked with less benefit when treated with antiepidermal growth factor receptor antibodies in metastatic colorectal cancer (mCRC). Targeting this molecular aberration has thus become a matter of particular interest in mCRC drug development. In contrast to other malignances such as BRAF mutant melanoma, efficacy observed with BRAF inhibitors in monotherapy in mCRC is poor. Several mechanisms of resistance have been identified leading to the development of different treatment strategies that have shown promising activity in early clinical trials. Hence, rational combination of targeted therapies is expected to further increase the efficacy of selective BRAF inhibitors. Herein, we discuss the main clinical and molecular characteristics of BRAF mutant colorectal cancer and its translation into the clinic, with a focus on developmental therapeutics and combination strategies. In addition, we contextualize the available data with potential future approaches that include the extended access to next-generation sequencing platforms and gene expression strategies for molecular subtyping. These approaches will facilitate the identification of certain patient profiles providing more therapeutic possibilities.
Introduction
The RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) signaling cascade-known as the mitogen-activated protein kinase (MAPK) pathway-drives cell proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway underlies many instances of tumorigenesis [1] . This pathway is composed of the RAS small guanidine triphosphatase (GTPase), which activates the RAF family proteins (ARAF, BRAF and CRAF, also known as RAF1). Activated RAF proteins lead to phosphorylation and activation of MEK1/2 proteins, which subsequently phosphorylate and activate ERKs. ERKs phosphorylate a variety of substrates, including multiple transcription factors and regulate several key cellular activities.
Aberrant signaling or inappropriate activation of the MAPK pathway has been shown in multiple tumor types, including melanoma, lung, pancreatic and colorectal (CRC) cancer, and can occur via several distinct mechanisms, including activating mutations in RAS and BRAF [2] . RAS and BRAF mutations are among the most frequent in human tumors. RAS mutations have been detected in 9%-30% of all cancers, with KRAS mutations the most prevalent (86%), then NRAS (11%) and HRAS only infrequently (3%) [3] . BRAF mutations are found in 7% of cancers, with BRAF V600E accounting for >90% of mutations in BRAFmutated cancers [4] . Between 8% and 12% of metastatic CRC (mCRC) cases harbor a BRAF mutation [5] [6] [7] [8] [9] [10] . Approximately 90% of all identified BRAF mutations are a T1799A transversion in exon 15 , which results in a valine amino acid substitution (V600E) [11] . This appears to mimic regulatory phosphorylation, increasing BRAF activity approximately 10-fold compared with wild-type [12] . Over the last decade, therapies targeting MAPK have been introduced in the treatment of mCRC. However, there are mutations that confer resistance to these therapies such as KRAS [13, 14] . Similarly, BRAF mutation may confer mCRC a worse prognosis and resistance to these therapies but at the same time a potential target for new drugs and combinations. This review aims to summarize the impact of BRAF mutation in early and advanced CRC as well as the current management and future perspectives in BRAF mutant (BRAF-mt) mCRC.
BRAF as an oncogenic driver in CRC: translation to the clinic BRAF and carcinogenesis CRC carcinogenesis may occur via different pathways. Compared with classic adenoma-carcinoma sequence where APC inactivation is the initiating event [15] , BRAF mutation is considered as a driver in serrated pathway and serrated polyps are consider its precursor lessions [16] . Serrated tumors are not chromosomal instable but often exhibit extensive DNA methylation of CpG islands. This methylation may occur in MLH1 promoter (a gene of the mismatch repair system) leading to 'sporadic' microsatellite instable (MSI) phenotype [17] . Sporadic MSI CRC is associated in 60% of tumors with BRAF mutation [10] . However, BRAF mutation is not observed in Lynch syndrome as microsatellite instability occurs via a different pathway based on germline mutations of the mismatch repair genes [18] .
BRAF as a prognostic factor
BRAF-mt CRC has been associated with a particular phenotype in several retrospective studies and meta-analysis. Later age at diagnosis and female sex are the main epidemiological features of BRAF-mt CRC patients [19] . BRAF mutation is more prevalent in proximal colon tumors; poorer differentiation, mucinous histology, MSI and larger primary tumors have been proposed as unique pathological features [20] [21] [22] . Metastatic spread seems to differ from BRAF wildtype (BRAF-WT) tumors with more peritoneal metastasis and less liver-limited and lung metastasis [8, 23] .
Although chemotherapy has significantly improved overall survival (OS) in CRC, response and treatment benefit appear lower for BRAF-mt tumors at both earlier and advanced disease stages. BRAF mutation (mainly V600E) seems to be an independent negative prognostic factor in stage II and III according to limited cohort studies [24] . Prospective mutational analysis from resected CRC patients included in the PETACC-3 study revealed poorer OS for those harbouring a BRAF mutation, with an even greater impact in stage III, although no impact in recurrence-free survival (RFS) was observed [25] . Nonetheless, as BRAF mutations are often associated with MSI tumors (considered a good prognostic in early stage), some studies have raised the question as to whether BRAF mutations impact two different populations: MSI and microsatellite stable (MSS). Main studies concerning this issue are reported in Table 1 [25] [26] [27] [28] . To sum up, BRAF mutation seems to be an independent negative prognosis factor in stage II and III MSS CRC. However, this could not be clearly stated for MSI CRC: the study reporting BRAF mutation as negative prognosis factor in MSI include up to 15% of mCRC patients whereas studies reporting no impact in MSI population include exclusively early stage CRC.
BRAF mutation also confers worse prognosis in the metastasic setting. The FOCUS trial, evaluating sequential treatment in CRC, reported worse OS for BRAF-mt CRC [hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.36-2.43], but no difference in progression-free survival (PFS) (HR, 1.14; 95% CI, 0.86-1.52) [7] . A pooled analysis of this trial along with the CAIRO, CAIRO 2 and COIN trials confirmed not only worse OS for BRAF-mt CRC (HR, 1.91; 95% CI, 1.66-2.15) but also a negative impact on PFS (HR, 1.34; 95% CI, 1.17-1.54) [29] . No significant survival differences were observed in BRAF-mt tumors irrespective of MSI status (HR, 1.05; 11.7 versus 11.3 months). Similar to early stage, when stratified by BRAF status, no significant survival difference was observed in MSI tumors. On the other hand, a decrease in OS was reported in BRAF-mt MSS tumors (Table 1) . Nonetheless, these results should be interpreted cautiously given the difference in MSI detection and study populations. Recently, Seligman et al. [30] published a pooled analysis of 2530 patients from three trials (FOCUS, PICCOLO and COIN) that included 231 patients with BRAF-mt mCRC. It was confirmed worse OS, but surprisingly, similar disease control rate and PFS compared with BRAF-wt. However, fewer BRAF-mt patients received the second-line treatment so this may justify why BRAF mutation has an impact in OS but not in PFS.
Survival in BRAF-mt populations after metastasectomy has been studied. For instance, Renaud et al. [31] retrospectively evaluated 180 lung metastasectomies in BRAF-mt, KRAS-mt and -WT CRC. BRAF-mt CRC showed significantly shorter OS after surgery compared with KRAS-mt or -WT (15, 55 and 98 months, respectively, P < 0.0001). Similar results were observed after liver metastasectomy [32] . In a retrospective study comprising 309 patients with liver resection, RFS was 5.7 months for BRAF-mt compared with 11.0 and 14.4 months for RAS-mt and RAS-WT, respectively (P ¼ 0.003). Risk of death was notably higher for BRAF-mt (HR, 3.07; P ¼ 0.002). Yaeger et al. [23] reported in a cohort of 1941 mCRC patients that BRAF-mt were less likely to have undergone a metastasectomy at 2 years (22% versus 41%; P < 0.01). Significant shorter 2-year OS (61% versus 86%; P ¼ 0.03) and a trend to shorter RFS after metastasectomy were reported (7 versus 11 months; P ¼ 0.084).
In conclusion, there is increasing evidence that BRAF mutation confers shorter survival in MSS early-stage and mCRC, but no definite conclusions can be drawn regarding MSI CRC. This issue could be due to the low frequency of both MSI and BRAF-mt CRC. However, these results take into account only the most prevalent mutation (V600E). Recently, BRAF mutations in two other codons (594 and 596) have been described in mCRC [33] . These tumors have a different phenotype compared with classical BRAF-mt (non-mucinous, no peritoneal spread and rectal) and OS was shown to be longer compared to BRAF V600E mt (62.0 versus 12.6 months; HR, 0.36; P ¼ 0.002). Data from a larger number of patients are needed.
BRAF as a predictive biomarker
Responses to treatment are limited in BRAF-mt CRC patients. A retrospective study reported no differences in PFS irrespective of whether oxaliplatin-or irinotecan-based chemotherapy was administered in the first-line setting (6.4 versus 5.4 months; P ¼ 0.99) [34] . A retrospective mutational status evaluation from the FOCUS trial did not show significant differences in treatment outcomes between patients with different KRAS or BRAF status. There is thus insufficient evidence to conclude that BRAF is a predictive biomarker for irinotecan or oxaliplatin, as patients benefit regardless their mutational status [7] . However, better responses are needed. Some authors have proposed more intensive treatment based on the combination of 5-fluoruracil, leucovorin, oxaliplatin, irinotecan and bevacizumab (FOLFOXIRI-Beva). To confirm a retrospective analysis of a prospective phase II trial evaluating this combination, Loupakis et al. [35] treated 15 BRAF-mt CRC patients with FOLFOXIRI-Beva. Results were initially encouraging with median PFS and OS of 11.8 and 24.1 months and a 72% response rate (RR). However, these results could not be confirmed in TRIBE phase III (study that compared FOLFOXIRI-Beva against FOLFIRI-Beva as upfront therapy mCRC) despite [36] . A nonsignificant trend toward improvements in OS (10.7 versus 19.0 months; HR, 0.84; 95% CI, 0.24-1.2), PFS (5.5 versus 7.5 months; HR, 0.57; 95% CI, 0.27-1.23) and RR (42% versus 55%; HR, 1.82; 95% CI, 0.30-8.78) was obtained for FOLFOXIRI-Beva. These results may be influenced by the limited sample size (28 patients with BRAF-mt mCRC). Nevertheless, FOLFOXIRI-Beva may be considered for these patients as improvement in OS, PFS and RR is high even not statistically significant.
Monoclonal antibodies targeting EGFR (cetuximab and panitumumab) have been introduced into routine mCRC treatment due to impressive results in the RAS-WT population. The predictive value of BRAF mutation for these treatments has not been well stablished. Some retrospective studies hypothesize that BRAF mutation may confer resistance to these drugs. For instance, no responses were observed in BRAF-mt mCRC patients who were treated with cetuximab-irinotecan [37] or cetuximab or panitumumab [38] . This clinical observation was confirmed in preclinical studies with cell lines. Based on these results, a number of clinical trials have evaluated anti-EGFR therapy in the metastatic setting, analyzing the impact of BRAF mutation (Table 2 ) [5, [39] [40] [41] [42] [43] [44] [45] [46] [47] . For all studies other than the PRIME trial, BRAF status was retrospectively analyzed. The PICCOLO study was the only one to show a statistically significant detrimental effect of anti-EGFR therapy in BRAF mt mCRC in terms of PFS; however, this was not confirmed for OS. None of the other studies showed statistical significance favoring or not anti-EGFR antibodies, again most likely explained by the small size of the BRAF-mt populations.
Given that individual results from these randomized trials were non-confirmatory, a number of meta-analyses have recently been published, with intriguing results. Pietrantonio et al. suggested a negative predictive value of BRAF mutation for anti-EGFR drugs [47, 48] . A total of 10 clinical trials, totaling 462 BRAF V600E-mt CRC patients, were analyzed. Cetuximab and panitumumab did not improve either PFS (HR, 0.88; P ¼ 0.33), OS (HR, 0.91; P ¼ 0.63) or RR (odds ratio, 1.31; P ¼ 0.25) compared with the control arm (standard chemotherapy or best supportive care). On the other hand, Rowland et al. [49] suggested that there is insufficient published evidence to discard anti-EGFR in BRAF-mt mCRC. Their meta-analysis was based on eight clinical trials with 351 BRAF-mt mCRC patients. The NORDIC and FIRE-3 trials were excluded because FLOX and bevacizumab could not be compared to FOLFOX/FOLFIRI. Other important differences in the methodological approach add to this difference with the former meta-analysis. Whereas Pietrantonio et al. [48] only evaluated the BRAF-mt population, Rowland et al. [49] also took into account BRAF-WT patients, allowing a comparison with BRAF-WT mCRC. Based on this statistical assumption, HR for OS benefit with anti-EGFR antibodies was 0.97 for RAS-WT/ BRAF-mt whereas the HR was 0.81 in RAS-WT/BRAF-WT patients (test of interaction P ¼ 0.43). Similar results were reported for PFS (HR: 0.86 for RAS-WT/BRAF-mt; RAS-WT/BRAF-WT 0.62) with a nonsignificant test of interaction (P ¼ 0.07). Rowland et al. [49] highlight that these differences may be due to chance and encourage further analysis of results from clinical trials with anti-EGFR therapy on the basis of BRAF status.
In summary, BRAF mutation does not predict response to standard chemotherapy, although some guidelines recommend considering triplet chemotherapy combined with bevacizumab to manage aggressive BRAF-mt mCRC in fit patients. Predictive value of anti-EGFR antibodies in BRAF-mt mCRC is still a matter of controversy but results suggest that BRAF-mt may not benefit from cetuximab or panitumumab. It is necessary therefore to discuss carefully with patients about this limited evidence and the incidence of toxicity such as rash or diarrhea. 
Clinical development of BRAF inhibition strategies
Monotherapy, doublet and triplet combinations with drugs targeting MAPK pathway have been tested in BRAF-mt CRC. Main published clinical trials are summarized in Table 3 .
Monotherapy strategies
Following successful results with BRAF inhibitors in BRAF-mt melanoma, these drugs were proposed as a targeted therapy for BRAF-mt CRC. However, results were unexpectedly disappointing compared to the clinical activity observed in melanoma. Kopetz et al. [50] led one of the first approaches with a BRAF inhibitor in previously-treated BRAF-mt mCRC, using the recommended phase II dose of vemurafenib for melanoma (960 mg b.i.d.) [51] in an expansion cohort. A total of 21 patients with centrally confirmed V600E-positive BRAF-mt CRC with evaluable or measurable disease were included. A confirmed partial response lasting 21 weeks and seven cases of stable disease lasting at least 8 weeks were reported. Median PFS was 2.1 months (range, 0.4-11.6 months), with two patients progression-free for >6 months. Median OS was 7.7 months (range, 1.4-13.1 months). As the authors pointed out when preliminary results were presented, clinical activity in previously-treated BRAF-mt mCRC was noticeably more modest compared to BRAF-mt melanoma. These results confirmed some activity with vemurafenib but it now appears that BRAF activation in mCRC is more sophisticated and intriguing than in melanoma, 
C, cetuximab; BSC, best supportive care; FLOX, 5-fluorouracil bolus þ leucovorin þ oxaliplatin; FOLFIRI, 5-fluorouracil bolus þ continuous infusion 5-fluorouracil þ leucovorin þ irinotecan; FOLFOX, 5-fluorouracil bolus þ continuous infusion 5-fluouracile þ leucovorin þ oxaliplatin; HR, hazard ratio; NA, nonavailable; NSS, not statistically significant; OR, odds ratio; P, panitumumab.
as will be further discussed in this review. In this trial, analysis of baseline tissue was performed as part of a biomarker program. Concurrent mutations, microsatellite instability, CpG island methylation, PTEN loss, EGFR expression and copy number alteration were analyzed; however, none of them were associated with clinical benefit. Surprisingly, concurrent KRAS and NRAS mutations were detected at low allele frequency in a subset of the patients' tumors (median, 0.21% allele frequency) and were apparent mechanisms of acquired resistance in vemurafenib-sensitive patientderived xenograft models. The BASKET trial (MO28072) was conducted between 2012 and 2014 [52] . This trial demonstrated that targeting BRAF mutation does not have the same impact in all histologies. No responses were observed in the 10 mCRC patients. Median PFS and OS were 4.5 months (95% CI, 1.0-5.5) and 9.3 months (95% CI, 5.6 to not reached), respectively. Due to these poor results and some preclinical evidence, an amendment was performed and vemurafenib was combined with cetuximab. Results will be presented later in this review.
Resistance to BRAF targeting monotherapy
The knowledge that CRC biology is more complex and heterogeneous than melanoma is supported by preclinical data suggesting that in contrast to melanoma, CRC cell lines express high levels of activated EGFR which convey a reactivation on MAPK pathway following BRAF inhibition [53, 54] . In these preclinical studies, anti-EGFR therapy with either small molecule inhibitors (erlotinib) or monoclonal antibodies (cetuximab) targeting EGFR rendered these cell lines sensitive to the BRAF inhibitor. Furthermore, activation of the PI3K/AKT pathway has also been hypothesized to explain resistance to BRAF inhibitors in BRAFmt CRC cells [55] . These preclinical data suggest that both EGFR activation and aberrant PI3K pathway signaling may underlie the limited therapeutic effect of BRAF inhibitor monotherapy in patients with BRAF-mt metastatic CRC. Thus, combining an EGFR inhibitor and/or a PI3K inhibitor may be a good approach to treating these tumors. However, there may be additional pathways involved in resistance. There is extensive crosstalk between the Wnt and MAPK pathways, suggesting that the two pathways synergize to control cell proliferation. Reports have shown that ERK directly phosphorylates and activates the Wnt co-receptor LRP6 and that both pathways regulate transcription of the protooncogene c-Myc [56, 57] . Consistent with these observations, in a murine model of BRAF V600-induced colon tumorigenesis, Wnt pathway activation was identified as an important step in the progression from intestinal hyperplasia to carcinoma [58] . Moreover, some alterations in the Wnt pathway such as RNF43 mutations have been identified more frequently in BRAF V600E-mt CRC patient samples (64.4% versus 13.1% in an unselected CRC population) [59] . RSPO fusions have also been identified. Both alterations enhance Wnt signaling in a Wnt liganddependent manner. These data strongly suggest that Wnt pathway activation, via genetic alterations in upstream Wnt pathway regulators, is crucial in BRAFV600E-mt CRC tumorigenesis. Therefore, combining drugs targeting both the MAPK and Wnt pathways may also prove to be an effective strategy in managing BRAF-mt CRC.
Doublet combinations as a strategy to overcome resistance in BRAF-mt CRC
Targeting BRAF and EGFR. In light of the possibility that anti-BRAF therapy resistance in BRAF-mt CRC is mediated via feedback activation of EGFR signaling [53, 54] , the BASKET trial was amended to include an assessment of the safety and efficacy of vemurafenib combined with cetuximab [52] . Twenty-seven additional patients with BRAF-mt mCRC received vemurafenib and cetuximab at the recommended combination doses. One response was observed, and while approximately half the patients had tumor regression they did not meet the standard criteria for a partial response. Median PFS and OS for patients receiving combination therapy were 3.7 months (95% CI, 1.8-5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Nonetheless it should be noted that the CRC patients were heavily pretreated having received a median of two lines of previous therapy (range, 1-6). Similarly, another study evaluated efficacy and safety of panitumumab and vemurafenib in 15 BRAF-mt mCRC patients after progression under at least one treatment in the advanced setting (NCT01791309) [60] . A total of 10 tumor regressions were reported; two of them had stable disease lasting over 6 months with acceptable tolerance.
On the other hand, dabrafenib is a potent selective inhibitor of BRAF kinase competing against ATP. Preliminary results of a phase I/II trial (MEK116833; NCT01750918) evaluating different combinations of panitumumab, dabrafenib and trametinib (MEK inhibitor) have been presented. An interim analysis of 20 patients receiving combined dabrafenib and panitumumab showed a 10% RR (one complete and one partial) was reported with an 80% rate of stable disease. Median duration of response was 6.9 months and PFS was 3.5 months. Predose and day 15 paired biopsies were analyzed showing a 23% reduction of pERK levels [61] [62] [63] .
Encorafenib (LGX818) is a highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/ MEK/ERK pathway in tumor cells expressing the BRAF V600E mutation. As is the case for vemurafenib, no responses have been observed with monotherapy [64] . Promising results were observed in a dose-escalation trial with encorafenib and cetuximab in 26 BRAF-mt CRC patients (LGX818X2103; NCT01719380) [65] [66] [67] . The RR was 23.1% (one complete, four partial and one unconfirmed partial response) and 14 patients achieved stable disease, representing a 54% clinical benefit rate. Median PFS was 3.7 months (range, 2.8-10.6). Exploratory analyses of biomarkers showed that BRAF amplification appeared to correlate with longer PFS. The main adverse events were vomiting and fatigue. Phase II trial results were recently unveiled [67, 68] for 50 patients treated with this doublet. Median PFS was 4.2 months and the overall RR was 22%. OS results were not yet mature at the time of presentation.
Targeting BRAF and MEK. As combining BRAF and MEK inhibition proved to be more effective in melanoma than only BRAF inhibition [69] , the same approach was also evaluated in BRAFmt CRC. Forty-three BRAF V600E-mt mCRC received dabrafenib (150 mg b.i.d.) combined with trametinib (1.5 mg o.d.) [70] . Results published by Corcoran et al. [54] confirmed some activity of this combination, but again, far away from the impressive results in melanoma. The RR was 12% (one complete and four partial responses), 24 patients achieved stable disease (56%), and 10 patients (23%) remained on treatment for more than 6 months. A pharmacodynamics assay based on paired biopsies confirmed a 47% decrease in phosphorylated ERK, which was greater than in melanoma patients treated even with dabrafenib alone. Rash, diarrhea and pyrexia were the most common toxicities. Although no increase in EGFR phosphorylation was detected, the authors suggested that this combination could be improved with the addition of an anti-EGFR to target feedback reactivation of the MAPK pathway.
Triplet drug combinations in BRAF-mt CRC
As BRAF inhibition can induce EGFR over-activation or PI3K pathway modulation, and preclinical studies have shown efficacy combining drugs targeting EGFR, MAPK and the PI3K pathway, triple combinations might be a better approach in BRAF-mt CRC.
Panitumumab, trametinib and dabrafenib. This combination was explored in the above-mentioned phase I/II trial MEK116833 [61, 62] . A total of 35 patients were enrolled in dose escalation , dabrafenib 150 mg b.i.d., trametinib 2 mg o.d.) . The overall RR was 21%, including one complete response, showing activity not only with full doses but also with lower dosages. Median PFS and duration of response were 4.1 and 5.4 months, respectively. OS was reported in ESMO 2016 to be 9.1 months but remain immature [63] . Compared with doublet therapy (dabrafenib and panitumumab), more diarrhea but less dermatologic toxicity was seen.
Encorafenib, cetuximab and alpelisib. Alpelisib (BYL719) specifically inhibits the alpha subunit of PI3K. Based on previous preclinical data of PI3K activation, a combination of a BRAF inhibitor, an anti-EGFR and alpelisib was evaluated in the LGX818X2103 study. Phase I dose escalation results from 28 refractory BRAF-mt CRC patients were encouraging with a 17.9% RR and PFS of 4.2 months, doubling outcomes observed with standard therapy in this setting [67] . Interestingly, the disease control rate was 93% for the triplet versus 77% for encorafenib and cetuximab. Randomized Phase II trial (encorafenib þ cetuximab vs encorafenib þ cetuximab þ alpelisib) results were presented at ASCO 2016 [68] . No statistically significant differences were detected compared to doublet therapy (encorafenib and cetuximab) after 73 events (HR, 0.69; P ¼ 0.064); overall RR was 27% (16%-41%). Toxicity appeared to increase with the triplet combination (79% versus 58% of adverse events) and anemia and hyperglycemia were more frequent with the triplet. Mature PFS and OS results will determine whether PI3K inhibition could add any benefit to BRAF and EGFR inhibition despite increasing toxicity. On the meantime the concomitant PI3K inhibition has been abandoned as a putative strategy to foster activity of anti-BRAF combos in light of this preliminary results and a phase III trial comparing encorafenib and cetuximab with or without binimetinib versus chemotherapy in the second or third-line has recently been initiated. A safety lead-in for the triplet combination has been initiated to confirm tolerability of the concomitant BRAF/MEK/EGFR inhibition. One possible explanation to this fact could lay in the election of alpelisib as PI3K inhibitor. As said before, Alpelisib is an alpha-PI3K inhibitor, drug that has demonstrated to be ineffective in inhibiting PI3K pathway signaling in the presence of molecular alterations leading to PTEN loss of function [71] . In the BRAF-mt CRC these alterations are present in near 40% of the cases thus accounting for the clinical failure of a bonafide strategy solidly demonstrated in pre-clinical models [59] .
Irinotecan and cetuximab with vemurafenib. In 2012, Yang et al. [72] , published preclinical data from BRAF V600E-mt CRC cell lines and xenografts evaluating combinations of vemurafenib with different therapies including capecitabine, bevacizumab, irinotecan, erlotinib and cetuximab. All doublet combinations achieved greater antitumor activity and survival than monotherapy. Of note, triple therapy with vemurafenib, cetuximab and irinotecan was superior to all doublet combinations in terms of tumor growth inhibition, except for vemurafenib and erlotinib. Based on these results, a phase I trial (NCT01787500) combining these three drugs was developed [73] . A total of 18 BRAF-mt mCRC patients were treated at three dose levels. The highest dose (vemurafenib 960 mg b.i.d., cetuximab 250 mg/m 2 weekly and irinotecan 180 mg/m 2 every 14 days) was the maximum tolerated dose. The RR was 35%, including one complete response. Median duration of response and PFS were 25 weeks and 7.7 months, respectively. Further evaluation in a randomized phase II trial combining irinotecan and cetuximab with or without vemurafenib was recently presented at ASCO GI 2017 (SWOG 1406) [74] . A total of 106 patients were enrolled and the primary objective (PFS) was met as PFS increased to 4.3 months with the addition of vemurafenib compared to the control arm (2.0 months) with an HR of 0.42 (P< 0.001). Response and disease control rates were also higher in the vemurafenib arm (16% versus 4% and 67% versus 22%, respectively). OS remains immature but crossover at progression was allowed.
Future directions
BRAF-mt CRC treatment has changed rapidly over the last 4 years. Growing opportunities for these tumors are moving directly from the bench to the bedside. New drugs such as Wnt pathway or cyclin-dependent kinase inhibitors combined with BRAF inhibitors are currently being evaluated in phase I and II trials. Introducing targeted therapy earlier in the disease, with or without chemotherapy is also under evaluation. The principal trials are summarized in Table 4 . Changes to the BRAF-mt treatment scenario are expected in the upcoming years. Furthermore, results with new drugs targeting MAPK pathway are eagerly awaited. For instance, new molecules targeting specifically both BRAF and C-RAF or ERK (downstream MAPK pathway mediators) have shown safety and efficacy in preclinical models and phase I development has recently started (NCT02607813; NCT02711345).
Nonetheless resistance to target therapy almost systematically develops, and has been a focus of research in order to both characterize and overcome it. A preclinical study published by Oddo et al. [75] showed reactivation of the MAPK pathway in resistant cells: KRAS, EGFR, MAP2K1 or BRAF mutations or amplifications have been reported. KRAS mutations have also been observed in circulating DNA plasma in a report of a resistant patient. The group also tested in vitro combinations in these resistant cells showing that ERK, BRAF and EGFR inhibitors combined may overcome acquired resistance. These combinations now need to be studied in clinical trials in an attempt to improve results in BRAF-mt CRC however safety profiles could potentially be a challenge. Similarly, Ahronian et al. reported in matched biopsies from patients treated with BRAF targeted therapies the emergence of KRAS amplification, BRAF amplification, and a MEK1 mutation in post-treatment biopsies [76] . These alterations lead to resistance that could be reversed with ERK inhibitors. MET amplification has been reported also as a resistance mechanism to BRAF inhibition that could be reversed with dual BRAF and MET inhibition (vemurafenib and crizotinib) [77] .
In the era of CRC molecular classification based on gene expression profiling, BRAF-mt tumors have played a main role. The Colorectal Cancer Consortium has suggested four different subtypes based on gene expression signatures. BRAF mutations have been observed in all four subtypes [78] . However, there is a clear enrichment in CMS1 (MSI immune subtype) which is characterized by more immune infiltration and worse survival after relapse, similar to classic BRAF-mt CRC. Before this classification, a distinct 64-gene expression signature was identified for BRAF-mt CRC with a 96% sensitivity and 86% specificity [79] . However, a subpopulation of BRAF-WT CRC has been shown to share the same signature. This subpopulation also has poorer survival similar to classic BRAF-mt CRC. Therefore, all tumors sharing this genetic signature have been named BRAF-like CRC and many investigations are ongoing to validate this and propose new therapies. Recently, Vecchione et al. [80] reported that RANBP2 (a gene encoding a protein which regulates microtubule organization in the mitotic spindle) is essential for survival in these tumors. In vitro and in vivo studies have suggested that vinorelbine as microtubule disruptor, may have significant efficacy in these tumors. A prospective study will be soon launched to confirm this hypothesis as part of the pan-European MoTriColor Project.
On the other hand, going further in the transcriptomic classification of BRAF-mt colorectal tumors, these entities appear to be heterogeneous [81] . Two subgroups have been identified from unsupervised clustering based on gene profile analysis, BM1 and BM2. BM1 displays activation of KRAS/AKT pathway, mTOR deregulation and epithelial-mesenchymal transition, whereas BM2 is characterized by deregulation of the cell cycle (high CDK1 and low cyclin D1 levels). BM1 has a worse prognosis and a different approach in treatment is recommended compared to BM2. For instance, BRAF/MEK/PI3K inhibition may give greater benefit to BM1 compared to CDK1 inhibition that may offer more benefit to BM2. These results may offer a new perspective for BRAF-mt CRC in order to classify and select better treatment beyond BRAF/EGFR blockade.
Finally, overlapping between MSI and BRAF mutation occur often in this population. In the era of immunotherapy in cancer, anti-PD1 drugs have been approved in MSI tumors including mCRC. However, the role of these antibodies in MSI BRAF-mt mCRC is still to be determined. Therefore, the best sequence (target therapy or checkpoint inhibitors) may be studied in the next future.
Conclusions
Despite its low prevalence (5%-8%), BRAF V600 CRC has been extensively studied due to the very poor prognosis. Although BRAF-mt is a negative prognosis factor in MSS CRC, this is not clearly observed in MSI CRC, mainly due to the low incidence of these molecular alterations. These tumors seem to be partially resistant to classic chemotherapy although some regimens such as FOLFOXIRI may be effective in the metastatic setting. The predictive role of the BRAF mutation is yet to be established but some data suggest a residual benefit from monoclonal antibodies such as cetuximab or panitumumab when given in monotherapy or in combination with chemo backbones. BRAF-mt CRC was expected to be a paradigm of targeted therapy given that inhibitors targeting this kinase have been widely developed. However, unlike melanoma, poor results have been reported in clinical trials evaluating BRAF inhibition. Preclinical studies suggest that these differences may be related to differential EGFR-mediated MAPK reactivation or alternative pathway modulation such as PI3K and Wnt. Doublet and triplet combinations of BRAF inhibitors with antibodies targeting EGFR, MEK and/or PI3K inhibitors have obtained encouraging results for these tumors in terms of RR, however significant work is still needed to raise the bar for PFS. Gene expression profiling has broadened BRAF-mt CRC to include some BRAF-WT tumors with a similar behavior. Due to the low prevalence of this mutation, it is necessary large-scale international collaborations for further investigations and phase II/III trials in order to improve survival of these patients.
